Support information on page: Psychotropic Drugs & Developmental Disabilities > Comorbid epilepsy approach > Antipsychotics

Antipsychotic	Incidence of Seizures (%)	Sources
Chlorpromazine
<900 mg/day	0.3-5.0	94,98,99
>1 g/day	10	94
Clozapine
All doses	1-10	90,91,93-97
<300 mg/day	1-2	89,92,95
300-600 mg/day	0.8-4.0	89,92,95
>600 mg/day	2.1-14.0	89,92,95
Fluphenazine	<1.0-1.2	92,94,97
Haloperidol	No reports of incidence
Mesoridazine	<1.0-1.2	92,94,97
Loxapine	19	99
Molindone	No reports of incidence
Olanzapinea	0.88	92
Perphenazine	<1.0-1.2	92,94,97
Pimozide	No reports of incidence
Prochlorperazine	<1.0-1.2	92,94,97
Quetiapineb	<1	92,94,97
Risperidonec	0.3	88
Thioridazine	<1.0-1.2	92,94,97
Thiothixene	No reports of incidence
Trifluoperazine	<1.0-1.2	92,94,97
Triflupromazine	<1.0-1.2	92,94,97

^aProduct information. Olanzapine (Zyprexa). Eli Lilly Company, Indianapolis, IN, 1997.
^bProduct information. Quetiapine (Seroquel). Zeneca Pharmaceuticals, Wilmington, DE, 1997.
^cProduct information. Risperidone (Risperdal). Jansen Pharmaceutica, Inc., Titusville, NJ, 1997.

From: Barry JJ and Huynh N. Psychotropic drug use in patients with epilepsy and developmental disabilities. In: Devinsky O and Westbrook LE, eds. Epilepsy and Developmental Disabilities. Boston: Butterworth-Heinemann; 2001;205-217.
With permission from Elsevier (www.elsevier.com).
Reviewed June 2004 by Steven C. Schachter, MD, epilepsy.com Editorial Board.